FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220778935> ?p ?o ?g. }

• W4220778935 endingPage "103740" @default.
• W4220778935 startingPage "103740" @default.
• W4220778935 abstract "In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7% of relapsing-remitting multiple sclerosis (RRMS) patients taking Ocrelizumab (OCR).The objective of this study was to investigate the effect of OCR on lymphocyte subtypes in MS patients with and without lymphopenia.Retrospective study comparing lymphocyte subtypes in OCR-treated MS patients with low (G1) and normal (G2) absolute lymphocyte count (ALC) at the six-month follow-up (cut-off: 1000 × 106/L). Mann Whitney U test was used to compare ALC, CD19, CD4 T, CD8 T and NK cell counts at baseline and at the six-month follow up between the two groups. A linear mixed model was applied to compare changes in ALC, and subset counts and proportions between patients with and without lymphopenia. We performed the same analyses in a subpopulation of naïve to treatment patients to exclude the possible influence of the previous disease modifying therapy (DMT) in the different kinetics observed between the two groups.One hundred sixty-seven patients were included (G1, n = 34; G2, n = 133). At the six-month follow-up, compared with baseline, in the whole population we observed a significant reduction in ALC (p<0.0001), CD19 (p<0.0001) and CD8 T (p<0.0288) lymphocytes. We also found and increase in CD4/CD8 ratio after six months of treatment (p = 0.0098). G1 showed a lower ALC than G2 at baseline. At six months, mean ALC was 896.41 ± 156.25 × 106/L in G1 and 1909.9 ± 629.07 × 106/L in G2. CD4 and CD8 T cell mean counts were lower (p < 0.0001) in G1 than G2. At the linear mixed model analysis, we found a more pronounced increase in CD8 T percentage in G2 than G1 (p = 0.008). In the naïve to treatment group fifty patients were included. CD4 and CD8 T cell mean counts at six months were lower (p = 0.0074 and p = 0.0032, respectively) in G1 than G2. At the linear mixed model analysis, we found a more pronounced decrease of CD8 T cell count in G1 than G2 (p = 0.0103). Furthermore, we found an increase in CD8 T percentage in G2 whereas a profound decrease of CD8 T percentage was observed in G1 (p = 0.0052). After adjusting for confounders, significantly positive correlations were noted between ALC and both CD4 and CD8 T cell counts. Negative correlation was observed between ALC and CD4/CD8 ratio driven by low CD8 T cell counts.OCR decreases ALC. Among T cells, the treatment predominantly impacts CD8 cells. However, CD8 T cell decrease was more pronounced in patients with lymphopenia. Further studies are needed to establish the relationship between the effect of OCR on ALC and CD8 T cells and its potential implication in the early clinical response and risk for viral infections." @default.
• W4220778935 created "2022-04-03" @default.
• W4220778935 creator A5003704445 @default.
• W4220778935 creator A5003835636 @default.
• W4220778935 creator A5006639733 @default.
• W4220778935 creator A5017126964 @default.
• W4220778935 creator A5046609494 @default.
• W4220778935 creator A5059668121 @default.
• W4220778935 creator A5063501464 @default.
• W4220778935 creator A5063943085 @default.
• W4220778935 creator A5074170004 @default.
• W4220778935 date "2022-04-01" @default.
• W4220778935 modified "2023-09-28" @default.
• W4220778935 title "Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells" @default.
• W4220778935 cites W2561881161 @default.
• W4220778935 cites W2801420363 @default.
• W4220778935 cites W3004673556 @default.
• W4220778935 cites W3024534661 @default.
• W4220778935 cites W3025939368 @default.
• W4220778935 cites W3031537150 @default.
• W4220778935 cites W3048238297 @default.
• W4220778935 cites W3120882765 @default.
• W4220778935 cites W3126296588 @default.
• W4220778935 cites W3182350146 @default.
• W4220778935 cites W3191810570 @default.
• W4220778935 doi "https://doi.org/10.1016/j.msard.2022.103740" @default.
• W4220778935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35305426" @default.
• W4220778935 hasPublicationYear "2022" @default.
• W4220778935 type Work @default.
• W4220778935 citedByCount "9" @default.
• W4220778935 countsByYear W42207789352022 @default.
• W4220778935 countsByYear W42207789352023 @default.
• W4220778935 crossrefType "journal-article" @default.
• W4220778935 hasAuthorship W4220778935A5003704445 @default.
• W4220778935 hasAuthorship W4220778935A5003835636 @default.
• W4220778935 hasAuthorship W4220778935A5006639733 @default.
• W4220778935 hasAuthorship W4220778935A5017126964 @default.
• W4220778935 hasAuthorship W4220778935A5046609494 @default.
• W4220778935 hasAuthorship W4220778935A5059668121 @default.
• W4220778935 hasAuthorship W4220778935A5063501464 @default.
• W4220778935 hasAuthorship W4220778935A5063943085 @default.
• W4220778935 hasAuthorship W4220778935A5074170004 @default.
• W4220778935 hasConcept C126322002 @default.
• W4220778935 hasConcept C167672396 @default.
• W4220778935 hasConcept C203014093 @default.
• W4220778935 hasConcept C2777761686 @default.
• W4220778935 hasConcept C2778843634 @default.
• W4220778935 hasConcept C2779338263 @default.
• W4220778935 hasConcept C2780640218 @default.
• W4220778935 hasConcept C2780653079 @default.
• W4220778935 hasConcept C2908647359 @default.
• W4220778935 hasConcept C71924100 @default.
• W4220778935 hasConcept C8891405 @default.
• W4220778935 hasConcept C90924648 @default.
• W4220778935 hasConcept C99454951 @default.
• W4220778935 hasConceptScore W4220778935C126322002 @default.
• W4220778935 hasConceptScore W4220778935C167672396 @default.
• W4220778935 hasConceptScore W4220778935C203014093 @default.
• W4220778935 hasConceptScore W4220778935C2777761686 @default.
• W4220778935 hasConceptScore W4220778935C2778843634 @default.
• W4220778935 hasConceptScore W4220778935C2779338263 @default.
• W4220778935 hasConceptScore W4220778935C2780640218 @default.
• W4220778935 hasConceptScore W4220778935C2780653079 @default.
• W4220778935 hasConceptScore W4220778935C2908647359 @default.
• W4220778935 hasConceptScore W4220778935C71924100 @default.
• W4220778935 hasConceptScore W4220778935C8891405 @default.
• W4220778935 hasConceptScore W4220778935C90924648 @default.
• W4220778935 hasConceptScore W4220778935C99454951 @default.
• W4220778935 hasLocation W42207789351 @default.
• W4220778935 hasLocation W42207789352 @default.
• W4220778935 hasOpenAccess W4220778935 @default.
• W4220778935 hasPrimaryLocation W42207789351 @default.
• W4220778935 hasRelatedWork W1977511616 @default.
• W4220778935 hasRelatedWork W2090531156 @default.
• W4220778935 hasRelatedWork W2272446420 @default.
• W4220778935 hasRelatedWork W2904697613 @default.
• W4220778935 hasRelatedWork W2904749964 @default.
• W4220778935 hasRelatedWork W2997394796 @default.
• W4220778935 hasRelatedWork W3034725616 @default.
• W4220778935 hasRelatedWork W3036083494 @default.
• W4220778935 hasRelatedWork W3206414309 @default.
• W4220778935 hasRelatedWork W4306253278 @default.
• W4220778935 hasVolume "60" @default.
• W4220778935 isParatext "false" @default.
• W4220778935 isRetracted "false" @default.
• W4220778935 workType "article" @default.